0.00Open0.00Pre Close0 Volume0 Open Interest340.00Strike Price0.00Turnover4954.53%IV-38.06%PremiumJan 17, 2025Expiry Date93.73Intrinsic Value100Multiplier-2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9965Delta0.0004Gamma2.63Leverage Ratio-62.9424Theta0.0000Rho-2.62Eff Leverage0.0001Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet